Pioglitazone-reduced insulin resistance in patient with Werner syndrome

Lancet

Volumn 350, Issue 9088, 1997, Pages 1365-

  Imano, Eiichi ^a   Kanda, Tsutomu ^b   Kawamori, Ryuzo ^b   Kajimoto, Yoshitaka ^b   Yamasaki, Yoshimitsu ^b  

^a OSAKA GENERAL MEDICAL CENTER   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PIOGLITAZONE;

ADULT; ARTICLE; BODY MASS; CASE REPORT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; WERNER SYNDROME;

EID: 0345647070     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)65135-5     Document Type: Article

References (5)

1. Yu CE, Oshima J, Fu YH, et al. Positional cloning of the Werner's syndrome gene. Science 1996; 272: 258-62.
2. Lehman JM, Moor LB, Smith-Oliver TA, Wilkison WO, Wilson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxiosome proliferator-activated receptory (PPARγ). J Biol Chem 1995; 270: 12953-56.
3. Mukherjee R, Jow L, Croston GE, Paterniti R Jr. Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARγ2 versus PPARγ1 and activation with retinoid X receptor agonists and antagonists. J Biol Chem 1997; 272: 8071-76.
4. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome prolifertor-activated receptor gene expression in human tissues. J Clin Invest 1997; 99: 2416-22.
5. Matsuhisa M, Shi ZQ, Wan C, et al. The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in allozan-induced diabetic dogs. Diabetes 1997; 46: 224-31.